Skip to content
PubMed This is a summary of 43 peer-reviewed journal articles Updated
Clinical Immunology

Mendelian Susceptibility to Mycobacterial Diseases due to partial JAK1 deficiency: A Patient Guide

At a Glance

Partial JAK1 deficiency is an exceptionally rare genetic immune condition that weakens the signal needed to control mycobacteria. Diagnosis requires JAK1 genetic and functional testing; care includes avoiding BCG and using prolonged, strain-specific antibiotics.

Mendelian Susceptibility to Mycobacterial Diseases (MSMD) due to partial JAK1 deficiency is an exceptionally rare genetic condition that fundamentally changes how a child’s immune system communicates [1]. While most parts of the immune system function normally for some infections, the condition predominantly affects antimycobacterial defense in the reported phenotype, but other infections and immune manifestations may occur [1]. This creates a specific vulnerability for a group of germs known as mycobacteria, including environmental bacteria found in soil and water, as well as the weakened strain of bacteria found in the BCG vaccine [2][3].

What is Known Versus What is Uncertain

Because this specific form of MSMD is so new to science—with only one extensively documented case in current medical literature to date—the journey for families often begins with a long search for answers and requires a highly specialized medical team [1]. Genotype-specific evidence is limited, and this guide does not replace your treating team’s plan.

At the heart of this condition is a signaling glitch involving a protein called JAK1. In a typical immune system, cells release a signal called Interferon-gamma (IFN-γ) to tell other cells to destroy invading mycobacteria [1]. This signal binds to the IFN-γ receptor on the outside of the cell. JAK1 and JAK2 are receptor-associated kinases that work inside the cell to help transmit this signal to proteins like STAT1 [1]. In children with a partial deficiency, this internal transmission is muffled [1]. Because the problem is in the downstream signaling rather than a lack of the signal itself, standard treatments like injections of recombinant IFN-γ may not be effective, as the cells remain unable to transmit the message properly [4][1].

Confirming a diagnosis of partial JAK1 deficiency is a precise process that goes beyond routine blood work. It involves molecular genetic testing to identify the specific mutation in the JAK1 gene, often alongside functional cytokine-pathway studies interpreted with expert genetic and immunologic correlation to prove that the immune cells cannot properly transmit the IFN-γ signal in a laboratory setting [1][5]. This level of detail is necessary because routine immune screenings often look completely normal, potentially leading to misdiagnoses or delay in proper care [1]. Understanding the exact genetic nature of the condition is also a critical safety measure for the entire family; the BCG vaccine must be avoided for the diagnosed child, and any newborn siblings must be tested for the known familial variants before receiving BCG, coordinated with clinical immunology [6][7].

The path forward for a child with this diagnosis focuses on vigilant monitoring and tailored infection management. Treatment typically involves prolonged courses of multiple antibiotics chosen specifically to combat the exact strain of mycobacteria involved [8][9]. While the road involves long-term medication and frequent check-ups with immunology and infectious disease experts, working closely with a team that understands this “muffled signal” in the immune system allows you to move from a period of uncertainty into a phase of proactive and empowered management of your child’s health.

Common questions in this guide

What does partial JAK1 deficiency mean in MSMD?
It is an exceptionally rare genetic immune condition in which a change affecting JAK1 weakens the internal signal that helps immune cells control mycobacteria. Children may be especially vulnerable to mycobacteria from the environment and to the weakened bacteria used in the BCG vaccine, while other infections or immune problems can also occur.
How is partial JAK1 deficiency confirmed?
Confirmation usually requires molecular genetic testing for a JAK1 mutation and laboratory studies of how immune cells respond to interferon-gamma. Specialists interpret these results with the child's clinical history because routine immune screening can appear normal.
Can normal immune blood tests rule out partial JAK1 deficiency?
No. Routine immune screening may look normal in partial JAK1 deficiency, so normal initial results do not exclude it. Molecular testing and functional pathway studies may still be needed when the clinical picture raises concern.
Why must children with partial JAK1 deficiency avoid the BCG vaccine?
BCG contains a weakened mycobacterial strain, and partial JAK1 deficiency can impair the immune signaling needed to control it. The diagnosed child should avoid BCG, and newborn siblings should be tested for a known familial variant before vaccination in coordination with clinical immunology.
Are interferon-gamma injections effective for partial JAK1 deficiency?
They may not be effective because the defect is downstream of the interferon-gamma receptor, where JAK1 helps transmit the signal inside the cell. The child's immunology team should use the genetic and functional results to guide treatment.
How are mycobacterial infections treated in children with partial JAK1 deficiency?
Treatment typically involves a prolonged course of multiple antibiotics selected for the specific mycobacterial strain. Regular follow-up with immunology and infectious disease specialists helps assess the response and manage the child's care during treatment.
How are long-term antibiotics monitored for safety?
Long-term antibiotic treatment should be supervised by infectious disease and immunology specialists, with regular follow-up to assess response and check for medication-related problems. The team can specify whether liver, kidney, or other monitoring is needed for the particular antibiotic combination.

Get notified when new evidence is published on Mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (9)
  1. 1

    Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteria.

    Daza-Cajigal V, Albuquerque AS, Young DF, et al.

    Frontiers in immunology 2022; (13()):888427 doi:10.3389/fimmu.2022.888427.

    PMID: 36159783
  2. 2

    Frequency of Mycobacterium bovis and mycobacteria in primary immunodeficiencies.

    Ulusoy E, Karaca NE, Aksu G, et al.

    Turk pediatri arsivi 2017; (52(3)):138-144 doi:10.5152/TurkPediatriArs.2017.5240.

    PMID: 29062247
  3. 3

    Pseudotumoral Pulmonary Mycobacterium avium Disease in a Patient on Ruxolitinib Therapy.

    Constantin AA, Iorga AL, Gaburici AD, Leonte I

    Diagnostics (Basel, Switzerland) 2026; (16(7)) doi:10.3390/diagnostics16071069.

    PMID: 41975780
  4. 4

    Mendelian susceptibility to mycobacterial diseases: State of the puzzle.

    Errami A, Bousfiha AA

    Qatar medical journal 2023; (2023(2)):25 doi:10.5339/qmj.2023.sqac.25.

    PMID: 38025345
  5. 5

    Loss of Janus Associated Kinase 1 Alters Urothelial Cell Function and Facilitates the Development of Bladder Cancer.

    Daza-Cajigal V, Albuquerque AS, Pearson J, et al.

    Frontiers in immunology 2019; (10()):2065 doi:10.3389/fimmu.2019.02065.

    PMID: 31552026
  6. 6

    Adverse reactions to Mycobacterium bovis bacille Calmette-Guérin vaccination against tuberculosis in Iranian children.

    Mahmoudi S, Khaheshi S, Pourakbari B, et al.

    Clinical and experimental vaccine research 2015; (4(2)):195-9 doi:10.7774/cevr.2015.4.2.195.

    PMID: 26273579
  7. 7

    Mendelian susceptibility to mycobacterial disease in tuberculosis-hyperendemic South Africa.

    Cornelissen HM, Glanzmann B, Van Coller A, et al.

    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2021; (111(10)):998-1005 doi:10.7196/SAMJ.2021.v111i10.15341.

    PMID: 34949297
  8. 8

    Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series.

    Mahdaviani SA, Fallahi M, Jamee M, et al.

    Annals of clinical microbiology and antimicrobials 2022; (21(1)):8 doi:10.1186/s12941-022-00500-y.

    PMID: 35232430
  9. 9

    Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children.

    Alsuhaibani M, Felimban G, Shoukri M, et al.

    International journal of pediatrics & adolescent medicine 2019; (6(2)):47-50 doi:10.1016/j.ijpam.2019.01.003.

    PMID: 31388545

This page is for informational purposes only and does not constitute medical advice about partial JAK1 deficiency or your child's care. Your child's clinical immunology, infectious disease, and genetics teams should guide testing, vaccines, and treatment decisions.